DEMAND FOR DIGNICAP® SYSTEM REMAINS STRONG AS 32 U.S. MEDICAL CENTERS ADD DIGNITANA’S SCALP COOLING DEVICE TO THEIR CANCER CARE SERVICES

DEMAND FOR DIGNICAP® SYSTEM REMAINS STRONG AS 32 U.S. MEDICAL CENTERS ADD
DIGNITANA’S FDA-CLEARED MEDICAL SCALP COOLING DEVICE TO THEIR CANCER CARE
SERVICES
Lund, Sweden—July 29, 2016—Dignitana AB, a world leader in medical scalp-cooling
technology, announced today that the DigniCap® scalp cooling system, which was
cleared in December 2015 by the FDA to effectively reduce the likelihood of
chemotherapy-induced hair loss in women with breast cancer, is now, or will soon
be available at 32 cancer treatment centers across the U.S. The DigniCap® system
is the first and only scalp cooling device to complete rigorous FDA clinical
trials in America, where seven out of ten patients with early-stage breast
cancer kept at least 50% of their hair.

On the heels of this recent FDA Clearance, medical centers across the country
have begun offering the DigniCap scalp cooling system as part of the
comprehensive cancer care treatment services they provide. Through funding from
a recent Private Placement and Rights Offering, Dignitana is rapidly expanding
its reach across America as demand for the medical device accelerates.
Agreements with 32 centers have now been signed, with several early adopters
ordering additional units within months of initial set up.

The following cancer treatment centers are the most recent U.S. sites to include
the DigniCap® scalp cooling system as part of their breast cancer treatment and
care regimens:

  · Avera                  · Mount Sinai Cancer Center
McKennan (http://www.av  West (http://www.roosevelthospitalnyc.org/index.aspx)
era.org/locations/mcken  New York, New York
nan/)                      · Norton Cancer
Sioux Falls, South       Institute (https://nortonhealthcare.com/Pages/cancer.as
Dakota                   px)
  · Beverly Hills        Louisville, Kentucky
Cancer                     · Tower Hematology Oncology Medical
Center (http://www.bhca  Group (http://cedars-sinai.edu/Tower
ncercenter.com/)         -Hematology/index.aspx), an affiliate of Cedars-Sinai
Beverly Hills,           Beverly Hills, California
California
  · Cedars-Sinai’s
Samuel Oschin
  Comprehensive Cancer
Institute (http://www.c
edars
-sinai.edu/Patients/Pro
grams-and
-Services/Cancer
-Institute/)
Los Angeles,
California

“Growth in the U.S. has been robust and consistently strong for the last seven
months,” said Jan Richardsson, Chief Executive Officer of Dignitana. “We are
pleased to be able to meet the growing demand for DigniCap, and excited to be
working with such prestigious medical centers to provide their patients with a
solution to one of the most emotionally traumatic side effects of chemotherapy.”

To date, the DigniCap system has announced unit installations at the following
U.S. medical centers: Bronson Battle Creek Cancer Care
Center (https://www.bronsonhealth.com/locations/bronson-battle-creek-cancer-care
-center/), Charleston Hematology Oncology Associates (https://www.choasc.com/),
Chesapeake Oncology and Hematology Associates (http://cohamed.org/), Florida
Cancer Specialists & Research Institute (https://www.flcancer.com/),
Hematology (http://mhpdoctor.com/) Oncology Consultants, a Division of Michigan
Healthcare Professionals, Menorah Medical
Center (http://menorahmedicalcenter.com/service/cancer-care), Mount Sinai Beth
Israel Cancer Center (https://www.wehealny.org/services/cancer/), Mount Sinai
Comprehensive Cancer Center (http://msccc.com/), Oncology & Hematology
Specialists (http://www.oncologyandhematology.net/), Orange County Blood and
Cancer Care (http://www.memorialcare.org/), The Angeles Clinic and Research
Institute (http://www.theangelesclinic.org/), an affiliate of Cedars-Sinai , The
C. Anthony and Jean Whittingham Cancer Center at Norwalk
Hospital (http://www.norwalkhospital.org/departments/breast-cancer-program-at
-norwalk-hospital), The START Center for Cancer
Care (http://thestartcenter.com/), The Dubin Breast Center at The Mount Sinai
Hospital (https://www.mountsinai.org/patient-care/service-areas/cancer/cancer
-services/dubin-breast-center), Toledo Clinic Cancer
Center (http://www.toledocliniccancercenters.com/), Stamford Health Bennett
Cancer Center (https://www.stamfordhealth.org/care-treatment/cancer/cancers-we
-treat/?gclid=CjwKEAjwgPe4BRCB66GG8PO69QkSJAC4EhHhbAjPU25khADPseaFC9eNQu0U9AFQ9V
Z 
EJSM0pbvejBoC2Pjw_wcB), UCHealth Lone Tree Health
Center (https://www.uchealth.org/Pages/OHAM/OrgUnitDetails.aspx?OrganizationalUn
i 
tId=165), UCHealth’s University of Colorado
Hospital (https://www.uchealth.org/metrodenver/Pages/default.aspx) and
University of Colorado Cancer
Center (http://www.ucdenver.edu/academics/colleges/medicalschool/centers/cancerc
e 
nter/Pages/CancerCenter.aspx), UCSF Helen Diller Family Comprehensive Cancer
Center (http://cancer.ucsf.edu/), UT Health Science Center San Antonio’s Cancer
Therapy & Research Center (http://www.uthscsa.edu/patient-care/ctrc), Wake
Forest Baptist Medical Center (http://www.wakehealth.edu/), and Weill Cornell
Medicine (http://weill.cornell.edu/) and NewYork
-Presbyterian (http://www.nyp.org/).

The DigniCap® scalp cooling system features a patented tight-fitting silicone
cooling cap that is placed directly on the head, and an outer neoprene cap that
insulates and secures the silicone cap. The cooling cap is connected to a
cooling and control unit with touch screen prompts. A liquid coolant circulates
throughout the silicone cap, delivering consistent and controlled cooling to all
areas of the scalp. The cap is fitted to the head, and the temperature of the
scalp is lowered, resulting in vasoconstriction with reduced delivery of
chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to
decreased intra follicular metabolic rate. These factors together reduce the
risk of chemotherapy-induced hair loss.
För ytterligare information vänligen kontakta:

Jan Richardsson
VD, Dignitana AB (publ)

Telefon: 046-16 30 92
E-post: jan.richardsson@dignitana.se
Om Dignitana AB (publ)
Dignitanas, med säte i Lund, affärsidé är att utveckla, tillverka och
marknadsföra den medicintekniska produkten DigniCap®. Dignitana bedriver en
kontinuerlig forskning och utveckling av nya användningsområden för DigniCap®.
Dignitanas aktier handlas på NASDAQ OMX First North med Erik Penser Bank som
Certified Adviser. För mer information gå in på: www.dignitana.se

Om skalpkylningssystemet DigniCap®
Dignitanas huvudprodukt - skalpkylningssystemet DigniCap® - är ett patenterat
system med syfte att eliminera eller kraftigt reducera håravfall för patienter
som genomgår cytostatikabehandling. DigniCap® erbjuder skalpkylning med jämn
kyla, hög effektivitet, säkerhet och acceptabel komfort.